Table 2 The relationship between CD44v6 and integrin-β1 mRNA expression and clinical pathological features of patients with PC
Pathological features | N | CD44v6 mRNA expression | P value | Integrin-β1 mRNA expression | P value | ||
|---|---|---|---|---|---|---|---|
High | Low | High | Low | ||||
Sex | 0.238 | 0.132 | |||||
Male | 27 | 12 (54.5%) | 15 (45.5%) | 13 (48.1%) | 14 (51.9%) | ||
Female | 27 | 10 (37.0%) | 17 (63.0%) | 8 (29.6%) | 19 (70.4%) | ||
Age | 0.921 | 0.810 | |||||
≤60 | 24 | 10 (41.7%) | 14 (58.3%) | 9 (37.5%) | 15 (62.5%) | ||
>60 | 30 | 12 (40.0%) | 18 (60.0%) | 12 (40.0%) | 18 (60.0%) | ||
Tumor location | 0.235 | 0.241 | |||||
Head and Body PC | 34 | 12 (35.3%) | 22 (64.7%) | 14 (41.2%) | 20 (58.8%) | ||
Tail PC | 20 | 10 (50.0%) | 10 (50.0%) | 7 (35.0%) | 13 (65.0%) | ||
Clinical stages | 0.016 | 0.023 | |||||
I+II | 21 | 4 (19.0%) | 17 (81.0%) | 4 (18.2%) | 18 (81.8%) | ||
III+IV | 33 | 18 (54.5%) | 15 (45.5%) | 17 (53.1%) | 15 (46.9%) | ||
Tumor differentiation | <0.01 | 0.067 | |||||
Poorly and Moderately | 33 | 7 (21.2%) | 26 (78.8%) | 9 (29.0%) | 22 (71.0%) | ||
Highly | 21 | 15 (71.4%) | 6 (28.6%) | 12 (52.2%) | 11 (47.8%) | ||
Tumor size (diameter) | 0.187 | 0.114 | |||||
≤4 cm | 25 | 8 (32.0%) | 17 (68.0%) | 7 (28.0%) | 18 (72.0%) | ||
>4 cm | 29 | 14 (48.3%) | 15 (51.7%) | 14 (48.3%) | 15 (51.7%) | ||
LNM | 0.028 | 0.034 | |||||
Negative | 20 | 4 (20.0%) | 16 (80.0%) | 6 (23.1%) | 20 (76.9%) | ||
Positive | 34 | 18 (52.9%) | 16 (47.1%) | 15 (53.6%) | 13 (46.4%) | ||
Liver metastasis | 0.020 | 0.028 | |||||
Negative | 24 | 5 (20.8%) | 19 (79.2%) | 5 (20.8%) | 19 (79.2%) | ||
Positive | 30 | 17 (56.7%) | 13 (43.3%) | 16 (53.3%) | 14 (46.7%) | ||
CA199(U/ml) | 0.887 | 0.165 | |||||
≤1000 | 18 | 7 (38.9%) | 11 (61.1%) | 5 (27.8%) | 13 (72.2%) | ||
>1000 | 36 | 15 (41.7%) | 21 (58.3%) | 16 (44.4%) | 20 (55.6%) | ||
KPS | 0.665 | 0.841 | |||||
≤80 | 25 | 11 (44.0%) | 14 (56.0%) | 10 (40.0%) | 15 (60.0%) | ||
>80 | 29 | 11 (37.9%) | 18 (62.1%) | 11 (37.9%) | 18 (62.1%) | ||